Literature DB >> 33079318

A Pituitary Society update to acromegaly management guidelines.

Maria Fleseriu1, Beverly M K Biller2, Pamela U Freda3, Monica R Gadelha4, Andrea Giustina5, Laurence Katznelson6, Mark E Molitch7, Susan L Samson8, Christian J Strasburger9, A J van der Lely10, Shlomo Melmed11.   

Abstract

Guidelines and consensus statements ensure that physicians managing acromegaly patients have access to current information on evidence-based treatments to optimize outcomes. Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Society invited acromegaly experts to critically review the current literature in the context of Endocrine Society guidelines and Acromegaly Consensus Group statements. This update focuses on how recent key advances affect treatment decision-making and outcomes, and also highlights the likely role of recently FDA-approved therapies as well as novel combination therapies within the treatment armamentarium.

Entities:  

Keywords:  Acromegaly; Growth hormone; Insulin-like growth factor I; Oral octreotide; Pegvisomant; Pituitary adenoma; Somatostatin receptor ligand

Year:  2020        PMID： 33079318     DOI： 10.1007/s11102-020-01091-7

Source DB:  PubMed          Journal:  Pituitary        ISSN： 1386-341X            Impact factor:   4.107


  79 in total

Review 1.  Expert consensus document: A consensus on the medical treatment of acromegaly.

Authors:  Andrea Giustina; Philippe Chanson; David Kleinberg; Marcello D Bronstein; David R Clemmons; Anne Klibanski; Aart J van der Lely; Christian J Strasburger; Steven W Lamberts; Ken K Y Ho; Felipe F Casanueva; Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2014-02-25       Impact factor: 43.330

2.  Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.

Authors:  Shlomo Melmed; Vera Popovic; Martin Bidlingmaier; Moises Mercado; Aart Jan van der Lely; Nienke Biermasz; Marek Bolanowski; Mihail Coculescu; Jochen Schopohl; Karoly Racz; Benjamin Glaser; Miklos Goth; Yona Greenman; Peter Trainer; Emese Mezosi; Ilan Shimon; Andrea Giustina; Márta Korbonits; Marcello D Bronstein; David Kleinberg; Sam Teichman; Irit Gliko-Kabir; Roni Mamluk; Asi Haviv; Christian Strasburger
Journal:  J Clin Endocrinol Metab       Date:  2015-02-09       Impact factor: 5.958

3.  Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.

Authors:  Ansgar Heck; Kyrre E Emblem; Olivera Casar-Borota; Jens Bollerslev; Geir Ringstad
Journal:  Endocrine       Date:  2015-10-16       Impact factor: 3.633

4.  Acromegaly: an endocrine society clinical practice guideline.

Authors:  Laurence Katznelson; Edward R Laws; Shlomo Melmed; Mark E Molitch; Mohammad Hassan Murad; Andrea Utz; John A H Wass
Journal:  J Clin Endocrinol Metab       Date:  2014-10-30       Impact factor: 5.958

5.  Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.

Authors:  Jessica Brzana; Chris G Yedinak; Sakir H Gultekin; Johnny B Delashaw; Maria Fleseriu
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

6.  An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies.

Authors:  Maria Fleseriu; Leon Fogelfeld; Murray B Gordon; Jill Sisco; Ross D Crosby; William H Ludlam; Asi Haviv; Susan D Mathias
Journal:  Pituitary       Date:  2020-08       Impact factor: 4.107

Review 7.  A Consensus Statement on acromegaly therapeutic outcomes.

Authors:  Shlomo Melmed; Marcello D Bronstein; Philippe Chanson; Anne Klibanski; Felipe F Casanueva; John A H Wass; Christian J Strasburger; Anton Luger; David R Clemmons; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2018-09       Impact factor: 43.330

8.  Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider.

Authors:  Eliza B Geer; Jill Sisco; Daphne T Adelman; William H Ludlam; Asi Haviv; Dana Gelbaum; Shuqian Liu; Susan D Mathias; Lizheng Shi
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

9.  Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.

Authors:  Susan L Samson; Lisa B Nachtigall; Maria Fleseriu; Murray B Gordon; Marek Bolanowski; Artak Labadzhyan; Ehud Ur; Mark Molitch; William H Ludlam; Gary Patou; Asi Haviv; Nienke Biermasz; Andrea Giustina; Peter J Trainer; Christian J Strasburger; Laurence Kennedy; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

10.  Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.

Authors:  Christian J Strasburger; Niki Karavitaki; Sylvère Störmann; Peter J Trainer; Ilonka Kreitschmann-Andermahr; Michael Droste; Márta Korbonits; Berit Feldmann; Kathrin Zopf; Violet Fazal Sanderson; David Schwicker; Dana Gelbaum; Asi Haviv; Martin Bidlingmaier; Nienke R Biermasz
Journal:  Eur J Endocrinol       Date:  2015-12-18       Impact factor: 6.664
View more
  28 in total

1.  Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.

Authors:  Roberto Salvatori; Pietro Maffei; Susan M Webb; Thierry Brue; Jane Loftus; Srinivas Rao Valluri; Roy Gomez; Michael P Wajnrajch; Maria Fleseriu
Journal:  Pituitary       Date:  2022-01-12       Impact factor: 4.107

2.  Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly.

Authors:  Sabrina Chiloiro; Denise Costa; Rosa Lauretta; Valeria Mercuri; Emilia Sbardella; Irene Samperi; Marialuisa Appetecchia; Antonio Bianchi; Antonella Giampietro; Patrizia Gargiulo; Andrea M Isidori; Maurizio Poggi; Alfredo Pontecorvi; Laura De Marinis
Journal:  Endocrine       Date:  2022-08-20       Impact factor: 3.925

Review 3.  Acromegaly and Colorectal Neoplasm: An Update.

Authors:  Leandro Kasuki; Bernardo Maia; Mônica R Gadelha
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

4.  The epidemiology and management patterns of pediatric pituitary tumors in the United States.

Authors:  Luz E Castellanos; Madhusmita Misra; Timothy R Smith; Edward R Laws; J Bryan Iorgulescu
Journal:  Pituitary       Date:  2021-01-12       Impact factor: 4.107

5.  Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study.

Authors:  Anthony Andre; Nicholas Squittieri; Satyashodhan B Patil
Journal:  Adv Ther       Date:  2021-05-04       Impact factor: 3.845

Review 6.  COVID-19 and the pituitary.

Authors:  Stefano Frara; Agnese Allora; Laura Castellino; Luigi di Filippo; Paola Loli; Andrea Giustina
Journal:  Pituitary       Date:  2021-05-03       Impact factor: 3.599

7.  Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas.

Authors:  Nicholas A Tritos; Pouneh K Fazeli; Ann McCormack; Susana M Mallea-Gil; Maria M Pineyro; Mirjam Christ-Crain; Stefano Frara; Artak Labadzhyan; Adriana G Ioachimescu; Ilan Shimon; Yutaka Takahashi; Mark Gurnell; Maria Fleseriu
Journal:  Pituitary       Date:  2021-07-20       Impact factor: 4.107

8.  Clinical features and complications of acromegaly at diagnosis are not all the same: data from two large referral centers.

Authors:  Elena V Varlamov; Dan Alexandru Niculescu; Swechya Banskota; Simona Andreea Galoiu; Catalina Poiana; Maria Fleseriu
Journal:  Endocr Connect       Date:  2021-07-05       Impact factor: 3.335

9.  Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity.

Authors:  Júnia R O L Schweizer; Katharina Schilbach; Michael Haenelt; Alexandre V Giannetti; Mariana F Bizzi; Beatriz S Soares; Eduardo Paulino; Jochen Schopohl; Sylvère Störmann; Antônio Ribeiro-Oliveira; Martin Bidlingmaier
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

Review 10.  Pasireotide in the Personalized Treatment of Acromegaly.

Authors:  Manel Puig-Domingo; Ignacio Bernabéu; Antonio Picó; Betina Biagetti; Joan Gil; Cristina Alvarez-Escolá; Mireia Jordà; Montserrat Marques-Pamies; Berta Soldevila; María-Angeles Gálvez; Rosa Cámara; Javier Aller; Cristina Lamas; Mónica Marazuela
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-16       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.